Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07671365
PHASE4

Angiotensin II for Post Cardiac Surgery Vasoplegia (ANGII_V)

Sponsor: Methodist Healthcare System of San Antonio

View on ClinicalTrials.gov

Summary

The goal of this study is to conduct a prospective trial implementing a modified version of the Emory Protocol for administering ANG II to patients with post cardiac bypass vasoplegia. The main questions we aim to answer are: 1.) does administration of improve mortality, 2.) does the administration of Ang II using the modified protocol shorten the time needed to reach optimal MAP, 3.) does the administration of Ang II using the modified protocol shorten length of stay in the ICU and hospital? Researchers will compare outcomes from the interventional group to historical controls who did not receive Ang II using the modified protocol.

Key Details

Gender

All

Age Range

18 Years - 94 Years

Study Type

INTERVENTIONAL

Enrollment

329

Start Date

2026-07

Completion Date

2030-08

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

Angiotensin II (Giapreza®)

Patients who have post cardiopulmonary bypass vasoplegia who are already on vasopressin 0.04 units/min, norepinephrine 0.1 mcg/kg/min will have Ang II initiated at 10 to 20 ng/kg/min and titrated by 10 ng/kg/min every 5 minutes to a maximum dose of 80 ng/kg/min.